The Market LogEnter at least 2 characters. Company and ticker searches are not case-sensitive.

Reporting owner

Manning Paul B

Reporting owner CIK 0001494695 · Director

View SEC filings ↗

These transactions appear in filings associated with this reporting owner. Jointly reported quantities and amounts are unallocated; they are not this owner's individual purchases or total holdings. Names and roles reflect the relevant filing, and a reporting owner may be a person or an organization.

Reset

Transaction timeline

Who reported an acquisition, and when the transaction occurred.

Reported acquisitions by transaction dateEach row is a reporting owner. Select a marker to open its transaction details. Jointly reported transactions appear for each associated reporting owner, without dividing quantities or amounts.Manning Paul BManning Paul BManning Paul B · September 30, 2026 · Stock award · Stock Option (Right to Buy)Manning Paul B · November 25, 2025 · Purchase · Series C Warrant (right to buy)Manning Paul B · November 25, 2025 · Purchase · Series C Warrant (right to buy)Manning Paul B · November 25, 2025 · Purchase · Common StockManning Paul B · November 25, 2025 · Purchase · Common StockNov 25, 2025Sep 30, 2026
PurchaseStock awardGift receivedExercise / conversionConversionOther acquisition

5 dated transactions · 1 of 1 reporting owners shown. Select one owner to focus the chart.

View timeline as a table
Transaction dateCompany / securityReporting ownersAcquisition type
Sep 30, 2026Candel Therapeutics, Inc.Stock Option (Right to Buy)Manning Paul BStock award
Nov 25, 2025Verrica Pharmaceuticals Inc.Series C Warrant (right to buy)Manning Paul BPurchase
Nov 25, 2025Verrica Pharmaceuticals Inc.Series C Warrant (right to buy)Manning Paul BPurchase
Nov 25, 2025Verrica Pharmaceuticals Inc.Common StockManning Paul BPurchase
Nov 25, 2025Verrica Pharmaceuticals Inc.Common StockManning Paul BPurchase

Only transactions on this page are shown. Date windows end on the latest transaction date in this sample. Joint filings may appear on more than one row. Sales are not included. Share-price charts use a separate data source.

Transactions in associated filings

Reported insider acquisitions, ordered by filing date, newest first. Currency is shown only when reported.
Filed / transactedCompanyReporting ownersType / securityQuantityPrice / reference valueDetails
Trade: Candel Therapeutics, Inc.CADL · company listingsStock awardStock Option (Right to Buy)Derivative security · Code A2,1898.676Value: 18,991.764Currency not specifiedView ↗
Trade: Verrica Pharmaceuticals Inc.VRCA · company listings
Manning Paul BDirector · 10% owner
PurchaseSeries C Warrant (right to buy)Derivative security · Code P687,690Not reported *Value: Not reportedCurrency not specifiedView ↗
Trade: Verrica Pharmaceuticals Inc.VRCA · company listings
Manning Paul BDirector · 10% owner
PurchaseSeries C Warrant (right to buy)Derivative security · Code P343,845Not reported *Value: Not reportedCurrency not specifiedView ↗
Trade: Verrica Pharmaceuticals Inc.VRCA · company listings
Manning Paul BDirector · 10% owner
PurchaseCommon StockNon-derivative security · Code P2,750,7624.2425Value: 11,670,107.785Currency not specifiedView ↗
Trade: Verrica Pharmaceuticals Inc.VRCA · company listings
Manning Paul BDirector · 10% owner
PurchaseCommon StockNon-derivative security · Code P1,375,3804.2425Value: 5,835,049.65Currency not specifiedView ↗